^
Association details:
| Biomarker: | PDGFRB overexpression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
Published date:
11/09/2020
Excerpt:
The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months)...The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.
DOI:
10.3892/mco.2020.2168
